– USA, CA – Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board of Directors, effective immediately.
Ms. Sandoval currently serves as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, previously served as Chief Commercial Officer of KYTHERA Biopharmaceuticals, and prior to that role, as Vice President of Global Marketing for Allergan.
Ms. Sandoval is filling the vacancy created by the resignation of Albert Cha, M.D., Ph.D., who has served on the Menlo Therapeutics Board of Directors since 2015. Menlo Therapeutics expresses its deep appreciation to Dr. Cha for his extraordinary service and contributions to Menlo’s evolution. Dr. Cha has resigned from the Menlo Board effective March 19th, prior to Ms. Sandoval’s appointment to the Board to fill the vacancy created by Dr. Cha’s resignation.
“We are delighted that Elisabeth is joining the Menlo Board. She brings extensive experience in drug commercialization and new product launches, particularly in dermatology. Menlo Therapeutics is starting the transition to building a commercial organization as we prepare for our Phase 3 clinical trial results expected in the first half of 2020 and a potential commercial launch of serlopitant in 2021, if the ongoing trials are successful and regulatory approval is obtained. Elisabeth’s extensive commercial experience will help guide our planned transition to a commercial organization,” stated Steve Basta, Chief Executive Officer of Menlo Therapeutics.
About Elisabeth Sandoval
In addition to her responsibilities as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine, Ms. Sandoval is also responsible for developing and leading the company’s medical affairs, investor relations, corporate communications and business development functions. Before joining Alder, she was Chief Commercial Officer for KYTHERA Biopharmaceuticals, where she led the commercial strategy and execution including the hiring and development of all commercial functions and launch of a first-in-class product prior to KYTHERA’s acquisition by Allergan. Before KYTHERA, Ms. Sandoval was Vice President of Marketing for Bausch and Lomb Surgical, leading all marketing strategy and execution globally. Prior to this position, Ms. Sandoval was Vice President of Global Marketing at Allergan with responsibility for developing the global commercial strategy for the Medical Aesthetics division and execution of key product launches. She spent 23 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval serves on the board of directors for Alastin Skincare, a privately held company. Ms. Sandoval began her career in research and development at Johnson & Johnson’s Ethicon division.
She holds an MBA from Pepperdine University and a B.S. in Biology from the University of California, Irvine.
About Menlo Therapeutics
Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The company’s clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a planned Phase 3 program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.